Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 16, 2026, titled ""Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYAr (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis"".